u/rania_marchand

Cross-border prescription recognition exists under EU rules but is conditional and narrower than commonly assumed, with requirements about the prescription’s form and content.

a lot of people plateau nicely at 10mg and never need 15

Pen or vial? The step sizes available differ and it changes this answer.

Asked a question here that turned out to be based on a mechanism confusion. Three people untangled it patiently.

How fast was the escalation in that protocol?

sulphur burps are unpleasant and they are not dangerous

the weight numbers are secondary to what this is being developed for

Has anything else changed in the same window?

What is intake actually looking like — fibre and water especially?

if it is severe or persistent that is a clinician question, not a board question

Right, and the tolerability data in the combination arms is the part worth reading properly rather than summarising.

The translation cost of dealing with a foreign pharmacy was the thing I had not budgeted for.

Push back: the evidence base here is thin enough that a confident ranking against the established compounds is not supportable.

smaller meals, earlier, is the boring advice that works

eating slower does more than most of the supplements people recommend

research material is not approved for human use, which is why the clinical record here is thin

That symptom is not the one being described upthread. Two different things with similar names and the answers are not interchangeable.

Came off sema and onto tirz with a two-week gap. The first month was flat and I assumed I had made a mistake. Month two it moved.

Sulphur burps for the first eight days after each step, then nothing. Predictable enough that I planned my week around it.

stepping every four weeks is a ceiling on speed, not a schedule you must hit

a lot of people plateau nicely at 10mg and never need 15

Appetite effect for me is flat across seven days. On sema it was a wave. Same person, different molecule.

switching from sema is not a dose conversion, there is no clean equivalence

Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use.

Not convinced. Amylin signalling is not a GLP-1 pathway and the mechanism you are proposing conflates them.

Assumed the weight numbers were the point and was corrected. They are secondary to what this is being developed for.

the reimbursement criteria are published in most member states

Are you quoting a diabetes trial or an obesity one?

Yes — 10mg being a genuine landing place for a lot of people is underrated. There is no medal for 15.

the first fortnight after a step is the worst of it, then it settles

Nobody warned me about nausea and I would have liked the warning. It was not dangerous, it was just deeply unpleasant and completely unexpected.

the fasting number is the one people fixate on and it moves last

Weekly dosing again, half-life in the same neighbourhood as sema, so a step change takes about a month to reach steady state. Judging a new step at day five is judging noise.

Agreed that pharmacy margin regulation explains a lot of the price differences people find mysterious.

Small fix — insulin secretion in this class is glucose-dependent, which is precisely why the risk you describe comes from the other agent.

dose for glycaemic control is not the same conversation as dose for weight

I would be careful here. "Everyone gets this" is not true, and it makes the people who get something unusual assume they are fine when they should be asking.